Healthcare -
Biotechnology - NASDAQ - US
$ 1.42
5.19 %
$ 3.56 M
Market Cap
0.0
P/E
1. INTRINSIC VALUE
Balance Sheet
ZyVersa Therapeutics, Inc.
| Current Assets | 3.35 M |
| Cash & Short-Term Investments | 3.14 M |
| Receivables | 0 |
| Other Current Assets | 215 K |
| Non-Current Assets | 18.8 M |
| Long-Term Investments | 0 |
| PP&E | 14.8 K |
| Other Non-Current Assets | 18.7 M |
| Current Liabilities | 10.2 M |
| Accounts Payable | 8.43 M |
| Short-Term Debt | 8.66 K |
| Other Current Liabilities | 1.75 M |
| Non-Current Liabilities | 845 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 845 K |
EFFICIENCY
Earnings Waterfall
ZyVersa Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 10.4 K |
| Gross Profit | -10.4 K |
| Operating Expenses | 14.4 M |
| Operating Income | -14.4 M |
| Other Expenses | 83.9 M |
| Net Income | -98.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ZyVersa Therapeutics, Inc.
| Net Income | -98.3 M |
| Depreciation & Amortization | 10.4 K |
| Capital Expenditures | -1 |
| Stock-Based Compensation | 1.19 M |
| Change in Working Capital | 2.6 M |
| Others | 95.4 M |
| Free Cash Flow | -8.72 M |
Wall Street Analysts Price Targets
ZyVersa Therapeutics, Inc.
ZVSA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ZVSA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ZyVersa Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.
globenewswire.com
- 1 month ago
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
globenewswire.com
- 1 month ago
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025. New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.
globenewswire.com
- 2 months ago
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells. Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.
globenewswire.com
- 2 months ago
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders. With weight loss, less inflammation is expected, but adipose tissue inflammation can persist long after weight loss.
globenewswire.com
- 2 months ago
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer's and Parkinson's diseases The newly published data show that obesity leads to progressive brain inflammation in a mouse model, and that the proinflammatory processes worsen with prolonged obesity and with increased age This research supports our selection of obesity with associated comorbidities as the lead indication for Inflammasome ASC Inhibitor IC 100 IC 100 inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes to attenuate damaging neurologic and systemic inflammation WESTON, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in the peer-reviewed journal, Aging Cell, demonstrating that obesity in older adults or prolonged duration of obesity in the younger population resulted in inflammation and suppression of neurotrophic/neuroprotective factors in the brain, indicating that age and duration of obesity are critical risk factors for neurodegenerative diseases.
globenewswire.com
- 2 months ago
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
globenewswire.com
- 3 months ago
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that Stephen C.
globenewswire.com
- 3 months ago
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100 since its license. WESTON, Fla.
globenewswire.com
- 3 months ago
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which is characterized by deposition of insoluble amyloid fibrils in tissues and organs disrupting their structure and function. Extracellular ASC interacts with serum amyloid A (SAA) released by the liver during inflammation, forming a scaffold that accelerates SAA aggregation into amyloid fibrils, which are deposited in tissues and organs.
globenewswire.com
- 5 months ago
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on elevated ASC levels in older adults (>60 years) who were cognitively normal at baseline but demonstrated cognitive decline one year later (NI) compared to ASC levels in those who: Were cognitively normal at both baseline and 1 year later (NN), and Were cognitively impaired at both baseline and one year later (II) Inflammasome-induced neuroinflammation has been associated with early stages of cognitive decline in dementia associated with Alzheimer's and Parkinson's diseases. Excessive inflammasome activation leads to cell death (pyroptosis) and systemic release of cell contents, including ASC that can be measured in the plasma.
globenewswire.com
- 5 months ago
8. Profile
Summary
ZyVersa Therapeutics, Inc. ZVSA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 3.56 M
Dividend Yield
0.00%
Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Contact
2200 N. Commerce Parkway, Weston, FL, 33326
https://www.zyversa.com
IPO
Date
Feb. 11, 2022
Employees
7
Officers
Mr. Peter Wolfe
Chief Financial Officer & Secretary
Mr. Stephen C. Glover
Co-Founder, Chairman, Chief Executive Officer & President
Ms. Melda Uzbil O'connell
Senior Vice President of Corporate Development
Dr. Pablo A. Guzman FACC, M.D.
Chief Medical Officer, Senior Vice President of Medical Affairs & Chairman of Renal Scientific Advisory Board
Ms. Karen A. Cashmere
Chief Commercial Officer